drugset / Trial / NCT00706719

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

NCT00706719

Phase 2 Completed 17 enrolled Repros Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.

Timeline

Start
2008-06
Primary completion
2009-07
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 25 mg Oral
Comparator Testosterone Small molecule 1 % Topical